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Overexpression of Fetuin-A Counteracts Ectopic
Mineralization in a Mouse Model of Pseudoxanthoma
Elasticum (Abcc6/)
Qiujie Jiang1, Florian Dibra1, Michael D. Lee1, Reid Oldenburg1 and Jouni Uitto1
The pathologic hallmark of pseudoxanthoma elasticum (PXE) is ectopic mineralization of soft connective
tissues. Recent studies have suggested that PXE is a metabolic disease, and perturbations in a number of
circulatory factors have been postulated. One of them is fetuin-A, a 60-kDa glycoprotein synthesized in the liver
and secreted into blood. Observations in targeted mutant mice (Ahsg/) and in cell culture model systems
have shown that fetuin-A is a powerful anti-mineralization factor in circulation, and the serum levels of fetuin-A
in patients with PXE as well as in a mouse model of PXE (Abcc6/) have been shown to be reduced by up to
30%. In this study, we tested the hypothesis that overexpression of fetuin-A in Abcc6/ mice counteracts the
ectopic mineralization. Delivery of an expression construct containing full-length mouse fetuin-A comple-
mentary DNA (cDNA), linked to a His-tag, to the liver of these mice resulted in elevated serum levels of this
protein. As a consequence, soft tissue mineralization, which is a characteristic of Abcc6/mice, was reduced by
B70% at 12 weeks of age, but the effect was transient when examined 4 weeks later. The results suggest that
normalization of serum fetuin-A, either through gene therapy approaches or by direct protein delivery to the
circulation, may offer strategies for treating PXE and perhaps other heritable disorders of soft tissue
mineralization.
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INTRODUCTION
Pseudoxanthoma elasticum (PXE), a heritable multi-system
disorder, is characterized by ectopic mineralization of soft
connective tissues, with primary clinical manifestations in the
skin, the eyes, and the cardiovascular system (Neldner and
Struk, 2002; Li et al., 2009). The classic forms of PXE are
caused by mutations in the ABCC6 gene, which encodes
ABCC6 protein, a putative transmembrane transporter expres-
sed primarily in the liver and the kidneys (Belinsky and
Kruh, 1999; Pfendner et al., 2007, 2008; Li et al., 2009). The
precise function of ABCC6, including its transport sub-
strate(s), and the detailed mechanisms of the aberrant
mineralization processes, are currently unknown. It is clear,
however, that the soft tissue mineralization has a critical role
in clinical manifestations, such as intermittent claudication,
gastric bleeding, and early myocardial infarcts in the cardio-
vascular system. Furthermore, mineralization of Bruch’s
membrane in the retina leads to angioid streaks and bleeding
in the eye, resulting in loss of visual acuity and blindness.
Finally, histopathology reveals that the yellowish papules and
inelastic plaques of the skin consist of accumulation of
mineralized connective tissue, primarily pleiomorphic elastic
fibers. Currently, there is no specific or effective treatment
for PXE, but prevention of ectopic mineralization would
be expected to ameliorate the clinical manifestations.
A number of gene/protein systems have been shown to
participate in the control of the mineralization processes
under physiologic conditions. For example, use of targeted
mutant mouse (‘‘knock-out’’) models have shown that
proteins, such as fetuin-A, matrix gla protein, osteocalcin,
and ankylosis protein, apparently prevent premature miner-
alization under physiologic homeostasis of normal serum
calcium and phosphate concentrations (Jahnen-Dechent
et al., 1997; Luo et al., 1997; Ryan, 2001; Wang et al.,
2005). In this study, we have focused on the potential of using
fetuin-A as an inhibitor of mineralization in a mouse model of
PXE (Abcc6/), which have been generated by targeted
ablation of the Abcc6 gene (Gorgels et al., 2005; Klement
et al., 2005). These mice recapitulate features of human PXE,
including extensive mineralization of soft connective tissues
in the skin, the eyes, and the cardiovascular system. Similar
to PXE, mineralization in these animals is late onset (B5–6
weeks of age), and the calcium deposition is progressive
throughout the life. A consistent finding in this mouse model
is early-onset and progressive mineralization of the connec-
tive tissue capsule surrounding the vibrissae in the muzzle
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skin, a feature that we have previously suggested to serve as
an early biomarker of the overall mineralization process
(Jiang et al., 2007). The mineralization of the connective
tissue capsule can be quantitated either by computerized
morphometric analysis after histopathologic stains or by
direct biochemical assay of calcium/phosphate content of the
muzzle skin.
Fetuin-A (also known as the a2-Heremans-Schmid
glycoprotein, the corresponding mouse gene symbol being
Ahsg) is a systemic inhibitor of mineralization (Scha¨fer et al.,
2003), and targeted ablation of the corresponding mouse
gene (Ahsg) results in extensive mineralization of connective
tissues, especially when the mice were placed on a diet
rich in minerals and vitamin D, or on normal diet when
the genetic deficiency was combined with a DBA/2 genetic
mouse background with propensity for mineralization
(Jahnen-Dechent et al., 1997). It is highly expressed in the
liver and secreted into circulation, and the plasma concen-
tration of fetuin-A varies with age (Yang et al., 1992; Kazi
et al., 1998). It should be noted that the Ahsg/ phenotype is
not associated with changes in serum calcium or phosphate
concentrations.
Two lines of evidence suggest that fetuin-A may contribute
to the aberrant mineralization process in PXE. First, we have
previously shown that fetuin-A, which is expressed in the
liver and subsequently transported in circulation, colocalizes
with the mineral deposits in the connective tissue capsule of
vibrissae in Abcc6/ mice (Jiang et al., 2007). This was
accompanied byB20% reduction in fetuin-A levels in serum
of Abcc6/ mice at 6 months of age when compared with
age-matched wild-type controls. Second, immunologic mea-
surements of fetuin-A levels in sera from 110 patients with
PXE revealed that fetuin-A concentrations in these indivi-
duals’ sera were lower than those in 80 healthy, unrelated
controls (0.55±0.11 vs 0.80±0.23 g l–1; mean±SD, respec-
tively; Po0.001) (Hendig et al., 2006). Thus, these studies
suggest that fetuin-A, a major systemic inhibitor of miner-
alization, is deficient in PXE, and restoration of normal fetuin-
A levels may counteract the progressive mineralization of
connective tissues in PXE.
RESULTS
Development and testing of the fetuin-A expression construct,
pLive-Fetuin-A
The purpose of this study was to overexpress fetuin-A in a
mouse model recapitulating features of PXE, including
ectopic connective tissue mineralization. The hypothesis
tested postulates that restoration of serum fetuin-A to normal
levels, or exceeding them, counteracts the pathogenic
mineralization process in this disease. For this purpose, an
expression construct pLive-Fetuin-A, consisting of an albumin
promoter and full-length mouse fetuin-A complementary
DNA (cDNA) linked to a His-tag, was developed (see
Materials and Methods). Several control experiments were
performed to ensure the expression of this construct. Mouse
liver epithelial cells were transfected with this expression
vector in culture, and the expression was followed by both
reverse transcriptase-PCR (RT-PCR) and immunofluorescence
(Figure 1). Before transfection, these cells express essentially
undetectable levels of fetuin-A messenger RNA (mRNA;
500 bp
1 2 3 4 5 6 7 8 9 10
Anti-HisAnti-mouse fetuin-A Merged
Figure 1. The expression of mouse fetuin-A in mouse liver epithelial (MLE) cells transfected with the pLive-Fetuin-A construct. (a) Reverse transcriptase-PCR
analysis reveals a 500-bp mRNA fragment in total RNA isolated from cells transfected with the pLive-Fetuin-A construct (lanes 1 and 2) and in positive control,
i.e., mouse liver mRNA (lane 6), whereas no corresponding transcript was observed in non-transfected cells (lanes 4 and 5) or in negative H2O control (lane 3).
The possibility of DNA contamination is excluded as no product was obtained when the same RNA samples were treated with RNase (lanes 7–9).
(b) Immunofluorescence of the MLE cells transfected with the pLive-Fetuin-A construct, using a goat anti-mouse fetuin-A antibody (left panel) and a mouse
anti-His antibody (middle panel), respectively. A merged image is on the right panel. Scale bar¼ 100mm.
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Figure 1a, lanes 4 and 5), whereas after transfection, a
specific band of 500 bp was readily observed using RT-PCR
(lanes 1 and 2). This band was similar to the band obtained
using mouse liver mRNA as template (Figure 1a, lane 6). The
possibility of DNA contamination was excluded by treatment
of the same RNA samples with RNase, which abolished the
signal (lanes 7–9). Immunofluorescence with anti-mouse
fetuin-A antibody stained a select population of transfected
mouse liver epithelial cells in culture, and the same cells
were positive for staining with an anti-His antibody
(Figure 1b). Merging of these images confirmed colocalization
of mouse fetuin-A and the His-tag epitopes in transfected
cells (Figure 1b). Collectively, these observations indicate
that the construct used for transfection was functional, leading
to expression of fetuin-A at both the mRNA and protein
levels.
Expression of the fetuin-A construct in the liver of Abcc6/
mice
Targeting of the expression constructs pLive-LacZ and pLive-
Fetuin-A to the liver in vivo was tested by injecting them into
the tail vein of Abcc6/ mice using the hydrodynamic
delivery method. This technique has been previously shown
to deliver expression constructs to the liver with high
efficiency (Zhang et al., 1999; Jiang et al., 2006). Injection
of 30 mg of pLive-LacZ construct confirmed expression of this
transgene in the liver by b-galactosidase staining of the entire
liver lobes en block (Figure 2a, upper panel) or by staining
paraffin sections of the liver (Figure 2a, lower panel). The
expression was clearly detectable at 1 week after injection,
seemed to be maximal at 2 weeks, and gradually declined
such that little if any expression was noticeable at 4 weeks.
The expression of the fetuin-A was examined by similar
injection of the pLive-Fetuin-A expression vector to the tail
vein of Abcc6/ mice. Serum samples were obtained from
the mice at 0, 2, 3, and 4 weeks after the injection, and the
level of fetuin-A was determined using ELISA. The data were
then compared with fetuin-A levels in Abcc6/ mice simul-
taneously injected with the pLive-LacZ vector. A significant,
close to 2-fold, increase in serum fetuin-A levels was noted
after 2 weeks of injection (Figure 2b). These results indicate
that the system allows significant expression of the injected
transgene to be expressed in the liver and this leads to a
significant increase of fetuin-A levels in the serum of the
corresponding mice.
The expression of fetuin-A, at 4 weeks after the second
injection, was also determined in the liver using quantitative
RT-PCR. Small, but significant (Po0.01) increase, B1.5-fold
on the average, of the mRNA levels was noted in the liver of
mice injected with the pLive-Fetuin-A construct when
compared with the pLive-LacZ vector (data not shown).
Expression of recombinant fetuin-A in the liver of the mice
injected with the pLive-Fetuin-A construct was also examined
using immunofluorescence with the antibody recognizing the
His-tag in the construct. Distinct cells with expression of the
construct were noted in mice treated with pLive-Fetuin-A,
whereas the immunofluorescence was negative in the control
mice treated with the LacZ expression construct (Figure 3a).
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Figure 2. Demonstration of the efficiency of gene delivery to the mouse liver. A total of 30 mg of the pLive-Fetuin-A or pLive-LacZ construct was injected
into the tail vein of Abcc6/ mice. (a) Targeting of gene delivery to the liver and gene expression were confirmed using b-galactosidase staining of either entire
livers en block (a, top panel) or paraffin sections of the liver (a, bottom panel) at 1–4 weeks after injection. (b) Serum samples were obtained from mice at 0, 2, 3,
and 4 weeks after tail vein injection of the pLive-Fetuin-A vector, and analyzed to determine the level of fetuin-A using ELISA. The data are presented as fold
change in the Abcc6/ mice treated with pLive-Fetuin-A compared with the Abcc6/ mice treated with pLive-LacZ construct (n¼ 4; mean±SE). A statistically
significant increase of serum fetuin-A in mice treated with the pLive-Fetuin-A construct was noted at 2 weeks after injection (*Po0.05). Scale bar¼ 100mm.
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Expression of the fetuin-A protein in the liver was also
examined using western analysis, which showed enhanced
expression in the mice treated with pLive-Fetuin-A construct
(Figure 3b).
Reduced mineralization of connective tissue in Abcc6/ mice
after overexpression of fetuin-A
The clinical correlate of this study revolves around the
hypothesis that overexpression of fetuin-A can counteract
the mineralization process in Abcc6/ mice. To specifically
test this hypothesis, we injected either the pLive-LacZ or
pLive-Fetuin-A vector targeting the liver as above. The
injections were repeated 4 weeks later, and the degree of
connective tissue mineralization was determined at 4 or
8 weeks after the second injection, i.e., at the age of 12
or 16 weeks of the mice. The fetuin-A levels in the serum of
mice injected with pLive-Fetuin-A construct examined at
12 weeks of age were significantly increased by approxi-
mately 2.5-fold (Figure 4a, left panel). Areas of muzzle skin
containing vibrissae were then biopsied and the total calcium
content was determined using a chemical assay. The content
of calcium, corrected for the tissue weight, was reduced in
the biopsies obtained from Abcc6/mice treated with pLive-
Fetuin-A when compared with the pLive-LacZ controls
(Figure 4a, middle panel). Reduced mineralization of the
connective capsule in vibrissae of Abcc6/ mice was also
shown by direct histopathologic evaluation upon staining
with hematoxylin and eosin (H&E) or Alizarin red (Figure 4b).
Computerized morphometric analysis of H&E-stained sec-
tions revealed that the Abcc6/ mice treated with the pLive-
Fetuin-A construct had over 70% decrease in the degree of
mineralization at 4 weeks subsequent to the second gene
delivery when compared with the age-matched control mice
treated with pLive-LacZ (Po0.05; Table 1).
Examination of the total cohort of 19 experimental mice at
12 weeks of age using regression analysis revealed an inverse
correlation between the calcium content of vibrissae and
fetuin-A serum concentration, specifically in the range of
o60 ngml–1 (Figure 4a, right panel). In concentrations higher
than that, the correlation was not apparent.
The extent of the fetuin-A expression was also examined in
mice at 8 weeks after the second gene delivery. At that point,
the fetuin-A levels in serum were not statistically different in
mice treated with pLive-Fetuin-A and pLive-LacZ (Figure 5a).
In addition, the difference in the calcium content of
the vibrissae noted at 4 weeks was not evident at 8 weeks
(Figure 5b and Table 1).
DISCUSSION
Putative pathomechanisms of PXE
PXE is a multi-system, autosomal recessive disorder char-
acterized by dystrophic mineralization of soft connective
tissues in a number of organs. Clinically, the manifestations of
classic PXE center on three major organ systems: the skin, the
eyes, and the cardiovascular system (Neldner, 1988; Li et al.,
2009). The primary cutaneous lesions are small yellowish
papules on the predilection sites at flexural areas, and the
lesions progressively coalesce into larger plaques of inelastic,
leathery skin. Histopathologic evaluation of skin reveals
accumulation of basophilic elastotic material, as revealed
using H&E stain, and characteristically these elastotic struc-
tures become mineralized in a progressive manner over the
pLive-fetuin-A
pLive-LacZ
pLive-LacZ
Fetuin-A
β-Actin
DAPI stain for nuclei Red signal for His protein Merged signals
pLive-fetuin-A
Figure 3. Expression of recombinant fetuin-A in mouse liver. The livers from Abcc6/ mice at 8 weeks after delivery of the pLive-Fetuin-A or pLive-LacZ
construct were subjected to fetuin-A protein determination. (a) Immunofluorescence was performed on paraffin sections obtained from control group
(lower panel) and experimental group of mice (upper panel) with an anti-His antibody. (b) Protein expression of fetuin-A in liver was also examined using
western blot analysis of liver extracts. The double bands represent different degrees of protein glycosylation. Each lane represents an individual mouse in
each group. Scale bar¼ 100 mm.
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lifetime of the affected individuals. Although PXE is asso-
ciated with considerable morbidity and occasional morta-
lity from cardiovascular complications, the phenotypic
spectrum is highly variable with both inter- and intra-familial
heterogeneity, and involvement of any given organ system
may predominate in certain families. This variability has
presented a diagnostic challenge, compounded by the fact
that clinical manifestations are rarely present at birth
and often do not become evident until the second or third
decade of life.
The classic form of PXE is caused by mutations in the
ABCC6 gene on chromosome 16p13.1, and to date over 300
distinct mutations have been described, representing over
1,000 mutant alleles (Hendig et al., 2005; Miksch et al.,
2005; Chassaing et al., 2007; Pfendner et al., 2007, 2008;
Vanakker et al., 2008). The types of mutations include mis-
sense and nonsense mutations in 28 of the 31 exons of the
gene, intronic mutations causing miss-splicing, small dele-
tions, and insertions, as well as large deletions spanning part
or the entire coding region and sometimes including flanking
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Figure 4. Demonstration of the effect of fetuin-A on the mineralization of connective tissue capsule surrounding vibrissae in the Abcc6/ mice. (a) Serum
fetuin-A levels (left panel) and levels of calcium in the muzzle skin containing vibrissae (middle panel) in Abcc6/ mice treated with pLive-Fetuin-A when
compared with the Abcc6/ mice treated with pLive-LacZ at 8 weeks after the first injection through tail vein. The calcium contents were determined
colorimetrically using o-cresolphthalein complexone normalized by tissue weight, and are presented as mean±SE (Po0.05; Student’s t-test). The correlation
between the degree of mineralization of the vibrissae and the serum levels of fetuin-A in individual mice of the experimental cohort of 19 mice at 12 weeks
of age (right panel). The overall correlation of all points is shown as power line with R2¼0.3296 (black line), whereas the linear inverse correlation of
fetuin-A concentration valueso60 ng ml–1 is shown as a red line with R2¼ 0.1705. (b) Sections of muzzle skin from Abcc6/ mice injected with pLive-Fetuin-A
(b, right) or pLive-LacZ (b, left), were stained with hematoxylin and eosin (H&E) or Alizarin red. Note that there is less mineralization in the connective
tissue capsule surrounding the vibrissae in pLive-Fetuin-A-injected group of mice when compared with the control group. Scale bar¼100 mm.
Table 1. Quantitation of mineralization of vibrissae1
Group2
Total vib.
per mouse3 (n)
Mineralized vib.
per mouse3 (n)
Percent
mineralized (%)
Area of mineralization
per total area4 (%) P-value
Contr., 12 weeks (male, n=9) 12.6 3.3 36.7 1.21±0.345 (1.11; 0–2.91) o0.055
Exp., 12 weeks (male; n=10) 14.3 1.5 12.5 0.34±0.167 (0.13; 0–1.47)
Contr., 16 weeks (female, n=3) 13.0 6.3 45.7 1.38±0.122 (1.39; 1.20–1.54) 40.056
Exp., 16 weeks (female; n=6) 9.6 3.8 42.7 1.24±0.362 (1.11; 0–2.67)
Abbreviations: Contr., control; Exp., experimental; vib., vibrissae.
1Skin sections from knockout mice at the age of 12 or 16 weeks, i.e., 8 or 12 weeks after DNA delivery, were stained with H&E, and examined for
mineralization using light microscopy, followed by quantitative computerized morphometric analysis.
2Control, Abcc6/ mice injected with pLive-LacZ; experimental, Abcc6/ mice injected with pLive-Fetuin-A.
3n, numbers of vibrissae examined.
4Values presented as mean±SE as well as median; range in parenthesis.
5P-value for comparison between Contr. 12-week and Exp. 12-week groups using Mann–Whitney U-test.
6P-value for comparison between Contr. 16-week and Exp. 16-week groups using Mann–Whitney U-test.
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genes as well. Identification of mutations in the ABCC6 gene
can be used for confirmation of the clinical diagnosis, carrier
detection, and pre-symptomatic identification of affected
individuals with a family history of PXE. In spite of the
impressive progress in molecular diagnostics in PXE, no clear
explanation for the phenotypic heterogeneity is currently
available, and careful comparisons of the mutation database
with phenotypic details have been unyielding (Pfendner
et al., 2007). It is evident, however, that the extensive and
progressive connective tissue mineralization, the pathologic
hallmark of PXE, is the cause of clinical findings in the
affected tissues.
We have previously suggested that PXE is a metabolic
disorder, and that in the absence of ABCC6 transporter
activity in the liver, serum becomes deficient of a factor(s)
necessary for prevention of aberrant, unwanted mineraliza-
tion under normal homeostatic calcium and phosphate
concentrations (Uitto et al., 2001; Jiang and Uitto, 2006).
This hypothesis has been supported by our grafting models of
Abcc6/ and wild-type mice, as well as by in vitro minerali-
zation models indicating that Abcc6/mouse serum has less
ability to prevent the mineral deposition induced by inorga-
nic phosphate in a cell culture system (Jiang et al., 2007,
2009). Thus, a number of serum factors, including fetuin-A,
matrix gla protein, osteocalcin, and ankylosis protein,
have been identified as potential candidate molecules for
perturbations in PXE.
The role of fetuin-A in the mineralization process in PXE
Fetuin-A is a 60-kDa glycoprotein implicated as an anti-
mineralization factor under physiologic conditions (Yang
et al., 1992; Scha¨fer et al., 2003). Specifically, targeted
ablation of the corresponding gene, Ahsg, results in severe
mineralization of soft connective tissues in mice, a process
exacerbated by diet rich in minerals and vitamin D and
amplified by genetic mouse background with propensity for
mineralization (Jahnen-Dechent et al., 1997). We have also
shown that in an in vitro aortic smooth muscle cell culture
system, fetuin-A counteracts inorganic phosphate-induced
mineralization in the presence of Abcc6/ mouse serum
(Jiang et al., 2007). In addition to these experimental data, the
fetuin-A levels in sera from patients with PXE as well as in
Abcc6/ mice have been found to be reduced by
approximately 20–30% in comparison with corresponding
controls (Hendig et al., 2006; Jiang et al., 2007). The genetic
evidence attesting to the role of fetuin-A as a systemic
inhibitor of mineralization has been complemented by
ultrastructural and biophysical data, suggesting that fetuin-A
forms colloidal spheres with calcium and phosphate that
remain soluble (Heiss et al., 2003). Conceptually, these
‘‘calciprotein particles’’ may provide a mechanistic explana-
tion as to how fetuin-A inhibits the mineralization process.
Extensive mutation analyses have also shown that the
calcium phosphate precipitation inhibitory activity by
fetuin-A resides in the amino-terminal cystatin-like domain
that consists of a dense array of acidic residues on the
extended b-sheet (Heiss et al., 2003).
Conclusions and clinical implications
The data presented in this study show that overexpression of
fetuin-A can prevent ectopic mineralization of connective
tissues in a mouse model of PXE developed by targeted
ablation of the Abcc6 gene. Evaluation of the entire
experimental cohort by regression analyses indicated a
reverse correlation between the mineralization process and
the serum fetuin-A concentrations at approximately
o60 ngml–1. At higher concentrations, no further reduction
in the degree of mineralization was noted, suggesting that
fetuin-A in serum has a critical target level beyond which no
further effect is elicited. It should be noted that the
introduction of fetuin-A expression construct to the liver
resulted in significant elevation of serum fetuin-A levels at 4
weeks after the second injection, but this elevation was
transient, as measurements at 8 weeks revealed no difference
in fetuin-A levels, and this was accompanied by similar levels
of calcium in the vibrissae. Thus, repeated or sustained
delivery of fetuin-A is required for long-term amelioration of
the mineralization process. These findings have also been
corroborated by in vitro findings in a cell culture system
(Jiang et al., 2007).
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Figure 5. The transient effect of DNA delivery on serum fetuin-A levels
and vibrissae calcium content. (a) Serum fetuin-A levels and (b) the calcium
content in the vibrissae of mice at 8 weeks after the second injection of
the pLive-Fetuin-A expression construct. The values, expressed as ±SE,
are not statistically different between pLive-Fetuin-A and the control groups
(Student’s t-test).
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Collectively, our observations suggest that fetuin-A could
potentially serve as a pharmacologic compound that could
halt, and even perhaps reverse, the mineralization process,
which is the principal cause of clinical manifestations in
PXE. Delivery of fetuin-A could use three potential strategies.
First, delivery of the expression vectors to the liver, with
subsequent integration to the genome, could potentially
allow sustained expression of this anti-mineralization protein,
analogous to the findings in our study. Second, ex vivo trans-
fection of hepatocytes or stem-cell populations with potential
for hepatocytic differentiation, with subsequent transplanta-
tion into the liver, would allow sustained expression of
the transgene. Finally, direct administration of recombinant
protein to the circulation could potentially elevate the
fetuin-A levels and counteract the mineralization process.
The latter strategy is obviously dependent on the stability and
half-life of the exogenously delivered protein. These issues
can be addressed experimentally in animal models, such as
the Abcc6/ mouse, and it is conceivable that with further
optimization of protein production and delivery, direct
protein replacement strategies can be developed toward
clinical application of treatment of this currently intractable
disease.
MATERIALS AND METHODS
Animals
All animal studies were performed in accordance with the
institutional guidelines of Thomas Jefferson University animal care
committee and the National Institutes of Health. Mice were placed
in cages in a temperature-controlled room with a 12-hour light–dark
cycle and free access to food and water.
In all studies, gender-matched Abcc6/ mice (4 weeks of age)
were used and divided into two groups: (1) the control group was
treated with the pLive-LacZ vector, and (2) the experimental group
was treated with the pLive-Fetuin-A vector (see below). Each group
consisted of 3 to 10 mice in each experiment. The mice were killed
at 4 or 8 weeks after the second injection (see below).
Vector construction
The pLive Vector, which contains an albumin promoter, has been
designed for prolonged, high-level expression of transgenes in
mouse liver, and pLive-LacZ reporter vector was purchased from
Mirus (Madison, WI). The pLive-Fetuin-A carrying the full-length
cDNA of the mouse fetuin-A was constructed as follows: The mouse
fetuin-A full length cDNA was first prepared by PCR amplification of
mouse liver cDNA using a sense (50-TTTTCGCGGCCGCTCTGGAG
CAA-30) and an antisense primer (50-CCAAAACCTTGCGGCCGCGA
ATC-30), both containing a NotI restriction site (underlined). The
PCR product was separated using agarose gel electrophoresis and
extracted from a gel slice (Qiagen, Valencia, CA). The purified
fragment was digested with NotI, and subcloned into pcDNA3.1c/
His vector (Invitrogen, Carlsbad, CA) to generate a full-length fetuin-
A cDNA linked to a His-tag at the 30 end. The cDNA fragment with
His-tag was then cloned after restriction digestion into the pLive
vector backbone. The fidelity of the cDNA sequences was verified
using automated DNA sequencing. Plasmid DNAs were purified
with Endofree Plasmid Maxi Kit (Qiagen) according to the
manufacturer’s protocol.
Transfection and expression analysis in vitro
Mouse liver epithelial cells were plated before transfection and
grown to approximately 80% confluency. The cells were transfected
with the pLive-Fetuin-A construct using FuGENE 6 transfec-
tion reagent according to the manufacturer’s instructions (Roche
Diagnostics, Indianapolis, IN). At 2 days after transfection, the
expression of mouse fetuin-A was analyzed at mRNA level using
RT-PCR and at protein level using immunofluorescence.
For RT-PCR, total RNA was extracted from transfected and
non-transfected mouse liver epithelial cells with RNeasy Mini Kit
(Qiagen) by applying the on-column DNase treatment, as recom-
mended by the manufacturer’s instructions. The amount and quality
of the RNA was verified by measuring the absorbance at 260/
280 nm. The RNA samples were split into two sets. One set was
treated with RNase before reverse transcription, whereas another set
of RNA was used directly for reverse transcription. Random-primed
reverse transcription of RNA was performed with the SuperScript
First-Strand Synthesis System for RT-PCR (Invitrogen), using 1mg of
RNA either treated with RNase or without such treatment. A total of
2ml of RT reaction products were used for PCR for amplifying mouse
fetuin-A cDNA. The primer sequences and the PCR conditions are
available from the corresponding author upon request.
To analyze the expression of fetuin-A and His-tag fusion protein
in the transfected cells, the cells were rinsed in 1 phosphate-
buffered saline, and then fixed in 50% methanol/acetone for 10
minutes, and blocked by 3% BSA for 1 hour at room temperature.
Cells were then incubated for 1 hour with the primary antibodies,
goat anti-mouse fetuin-A (1:200, R&D Systems, Minneapolis, MN)
and mouse anti-His tag (Qiagen), respectively. The secondary
antibody, either FITC conjugated anti-goat IgG or Texas Red
conjugated anti-mouse (Jackson ImmunoResearch West Grove,
PA), at 1:250 dilution, was applied for 1 hour.
Vector administration in vivo
A total of 30 mg pLive-Fetuin-A or pLive-LacZ construct was
delivered into the livers of 4-week-old Abcc6/ mice by hydro-
dynamic tail vein injection of 10% body volume of TransIT-QR
hydrodynamic delivery solution (Mirus), as recommended by the
manufacturer’s instructions, using a 27-gauge syringe needle. Two
separate injections were performed at 4 weeks apart.
X-gal staining
To analyze the liver biodistribution and expression of the pLive-LacZ
vector, livers were isolated from control group at 1–4 weeks after
injection and examined for b-galactosidase expression, using either
paraffin-embedded sections or entire liver lobes. Sections, 6 mm
thick, or liver lobes fixed with 4% paraformaldehyde were stained
for X-gal using the InvivoGen LacZ Detection kit (San Diego, CA).
The sections were lightly counterstained with eosin before mounting.
ELISA
Serum samples were collected from the mice at 1–4 weeks after
injection. Fetuin-A levels in mouse serum were determined
using indirect ELISA. Then, 96-well immunoplates (Nalge Nunc
International, Rochester, NY) were coated overnight at 4 1C with a
monoclonal anti-mouse fetuin-A antibody (R&D Systems),
50 ngwell–1. The wells were washed three times with phosphate-
buffered saline/0.05% Tween and then blocked with 5% BSA at
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room temperature for 2 hours. A standard curve was constructed
by adding recombinant mouse fetuin-A in concentrations up to
50 ngml–1. For assay of mouse serum levels of fetuin-A, serum in
1:5,000 dilution was added. After appropriate incubations and
washings, biotinylated goat anti-mouse fetuin-A antibody, 1:1,000
dilution, was added, followed by incubation for 1 hour at room
temperature and washings. Horseradish peroxidase-avidin (Zymed,
South San Francisco, CA) was then added, incubated for 1 hour,
washed five times with phosphate-buffered saline/0.05% Tween,
followed by color development using tetramethylbenzidine solution
(Pierce, Rockford, IL) in 2M H2SO4; the optical density was read
at 450 nm.
Western blot
Proteins were isolated from treated Abcc6/ mouse livers at 8
weeks after the first injection and subjected to SDS-PAGE (7.5% gel)
in the presence of a reducing agent. Protein was electrotransferred to
polyvinylidene fluoride membrane, and nonspecific binding sites on
the membrane were blocked by incubation in 5% milk for 1 hour at
room temperature. The blot was incubated with anti-fetuin-A
antibody at 1:1,000 dilution overnight at 4 1C, and then incubated
with horseradish peroxidase-labeled anti-goat secondary antibody at
1:80,000 dilution for 1 hour at room temperature. After three
10minutes washings, the signal was determined using ECL
Plus Western Blotting Reagent Pack (Amersham Biosciences,
Piscataway, NJ).
Quantitative RT-PCR
Total RNA extraction and random-primed reverse transcription of
RNA were performed as described above. SYBR Green PCR
amplification of mouse fetuin-A was performed in a model 7000
sequence detector (Applied Biosystems, Foster City, CA). The
reactions were carried out in a 96-well plate in a 25 ml reaction
volume containing 12.5ml of 2 SYBR Green PCR Master Mix
(Applied Biosystems), 0.3 nM concentration of forward and reverse
primer each, and 10 ng of cDNA. Liver cDNA samples in triplicate
were used for each run with a standard protocol. The amount of
specific mRNA in each RNA sample was quantified and normalized
to glyceraldehyde-3-phosphate dehydrogenase mRNA. The relative
expression level of the target genes was calculated using the DDCt
method (Real-time PCR software; model 7000 sequence detector;
Applied Biosystems). Reaction specificity was determined by the
dissociation curve immediately after the last reaction cycle, and
visualized with the software Dissociation Curve 1.0 (7000 sequence
detection system; Applied Biosystems).
Calcification measurement
Muzzle skin from both sides was harvested at 8 weeks after the first
injection. One side of tissue was decalcified with 0.15N hydro-
chloric acid for 48 hours at room temperature. The calcium content
was measured colorimetrically by the o-cresolphthalein complexone
method (CALCIUM (CPC) LIQUICOLOR, Stanbio Laboratory,
Boerne, TX), and the values for calcium were normalized to tissue
weight.
The other side of tissue was embedded in paraffin and 6-mm
sections were prepared for H&E or Alizarin red staining. Computer-
ized morphometric analysis of H&E-stained sections of muzzle skin
was performed, and specifically, the sections were examined with
a Nikon model TE2000 microscope equipped with an AutoQuant
Imaging system (Watervliet, New York, NY). The number of
vibrissae, with and without evidence of mineralization, was deter-
mined in several microscopic fields, and the degree of mineraliza-
tion was expressed as both the percentage of the mineralized
vibrissae and the percentage of area of mineralization per area of
vibrissae (Jiang et al., 2007; LaRusso et al., 2008, 2009).
Statistical analysis
Results are given as mean±SE and/or median plus range. The data
were first tested using Shapiro’s test for their distribution, and
the normally distributed data were analyzed using Student’s t-test.
Mann–Whitney U-test was used for the data not in normal
distribution. The differences were considered statistically significant
at Po0.05. The correlation between the serum fetuin-A levels and
the degree of mineralization of vibrissae, determined using chemical
calcium assay, was tested by regression analysis using Microsoft
Excel program.
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